Skip to content
Peptigraph home

Survodutide Phase 2 trial (NCT04153929)

A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
413
actual
Start
30 Apr 2020 (actual)
Primary completion
8 Oct 2021 (actual)
Sponsor
Boehringer Ingelheim
Design

Arms and doses

NCT04153929 study arms
ArmTypeInterventionsDescription
BI 456906 0.3 mgExperimentalDrug: BI 456906Not stated
BI 456906 0.9 mgExperimentalDrug: BI 456906Not stated
BI 456906 1.8 mgExperimentalDrug: BI 456906Not stated
BI 456906 2.7 mgExperimentalDrug: BI 456906Not stated
BI 456906 1.2 twice weekly (2.4) mgExperimentalDrug: BI 456906Not stated
BI 456906 1.8 twice weekly (3.6) mgExperimentalDrug: BI 456906Not stated
SemaglutideActive comparatorDrug: SemaglutideNot stated
PlaceboPlacebo comparatorDrug: PlaceboNot stated
Endpoints

Primary endpoint

NCT04153929 primary outcomes
MeasureTime frame
Absolute Change in HbA1c From Baseline to 16 WeeksAt baseline and at Week 17 (16 weeks after treatment start).
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04153929 secondary outcomes
MeasureTime frame
Key Secondary Endpoint: The Relative Change in Body Weight From Baseline to 16 WeeksAt baseline and at Week 17 (16 weeks after treatment start ).
The Absolute Change in Body Weight From Baseline to 16 WeeksAt baseline and at Week 17 (16 weeks after treatment start).
The Absolute Change in Waist Circumference From Baseline to 16 WeeksAt baseline and at Week 17 (16 weeks after treatment start).
Percentage of Patients With 5 % or Greater Body Weight Loss From Baseline to 16 WeeksAt baseline and at Week 17 (16 weeks after treatment start).
Percentage of Patients With 10% or Greater Body Weight Loss From Baseline to 16 WeeksAt baseline and at Week 17 (16 weeks after treatment start).
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04153929.

Survodutide in type 2 diabetes, dose-response against semaglutide

Participants with type 2 diabetes on metformin were randomised across six survodutide dose groups, placebo, or open-label semaglutide up to 1.0 mg weekly.[2]

The HbA1c reduction was similar for low-dose survodutide (-1.46%) and semaglutide (-1.47%).[2]

Bodyweight fell by up to 8.7% on survodutide, and doses of 1.8 mg weekly or more outperformed semaglutide (-5.3%).[2]

Adverse events, mainly gastrointestinal, were reported for 77.8% of survodutide recipients, 52.5% on placebo and 52.0% on semaglutide.[2]

Sources

  1. 1A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia · 2024PMID 38095657Accessed 2 Oct 2026

Found an error? Report a correction.